S Stintzing

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. doi request reprint Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group
    Nicolas Moosmann
    University of Munich, Klinikum Muenchen Grosshadern, Germany
    J Clin Oncol 29:1050-8. 2011
  2. doi request reprint Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels
    Sebastian Stintzing
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    Anticancer Drugs 24:969-74. 2013
  3. doi request reprint Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases
    Sebastian Stintzing
    Department of Medical Oncology and Comprehensive Cancer Center, Klinikum Grosshadern, LMU, Munich, Germany
    Acta Oncol 52:971-7. 2013
  4. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
  5. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
  6. doi request reprint Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis
    Sebastian Stintzing
    Department of Medicine III, University Hospital Grosshadern, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Virchows Arch 455:171-85. 2009
  7. doi request reprint Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients
    S Stintzing
    Department of Hematology and Oncology, University Hospital Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Eur J Cancer 46:1026-32. 2010
  8. doi request reprint Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors
    Sebastian Stintzing
    Department of Hematology and Oncology, University Hospital Grosshadern, LMU Munich, Munich, Germany
    Ann Surg Oncol 17:2877-83. 2010
  9. ncbi request reprint Role of cannabinoid receptors and RAGE in inflammatory bowel disease
    Sebastian Stintzing
    Department of Medicine III, University Hospital Grosshadern, Marchioninistrasse 15, Munich, Germany
    Histol Histopathol 26:735-45. 2011
  10. pmc Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
    C Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Br J Cancer 109:1428-36. 2013

Detail Information

Publications15

  1. doi request reprint Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group
    Nicolas Moosmann
    University of Munich, Klinikum Muenchen Grosshadern, Germany
    J Clin Oncol 29:1050-8. 2011
    ....
  2. doi request reprint Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels
    Sebastian Stintzing
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    Anticancer Drugs 24:969-74. 2013
    ..In mCRC patients treated with cetuximab, day-14 magnesium serum levels correlated with treatment efficacy...
  3. doi request reprint Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases
    Sebastian Stintzing
    Department of Medical Oncology and Comprehensive Cancer Center, Klinikum Grosshadern, LMU, Munich, Germany
    Acta Oncol 52:971-7. 2013
    ..In this analysis, two local therapies: 1) single session robotic radiosurgery (RRS) and 2) percutaneous radiofrequency ablation (RFA) were compared in a total of 60 heavily pretreated colorectal cancer patients...
  4. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
    ..This effect of Cet-ST is independent of the KRAS mutation status, suggesting that Cet-ST rather relates to constitutional factors of the patient than alterations of the EGFR pathway in the tumour...
  5. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...
  6. doi request reprint Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis
    Sebastian Stintzing
    Department of Medicine III, University Hospital Grosshadern, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Virchows Arch 455:171-85. 2009
    ....
  7. doi request reprint Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients
    S Stintzing
    Department of Hematology and Oncology, University Hospital Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Eur J Cancer 46:1026-32. 2010
    ..Less invasive techniques have been invented to enhance local disease control. We investigated in a selected patient cohort local control of liver metastasis from CRC using robotic radiosurgery...
  8. doi request reprint Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors
    Sebastian Stintzing
    Department of Hematology and Oncology, University Hospital Grosshadern, LMU Munich, Munich, Germany
    Ann Surg Oncol 17:2877-83. 2010
    ..Here we present the therapeutic efficacy of a robotic radiosurgery for local control of liver metastases from solid tumors...
  9. ncbi request reprint Role of cannabinoid receptors and RAGE in inflammatory bowel disease
    Sebastian Stintzing
    Department of Medicine III, University Hospital Grosshadern, Marchioninistrasse 15, Munich, Germany
    Histol Histopathol 26:735-45. 2011
    ....
  10. pmc Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
    C Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Br J Cancer 109:1428-36. 2013
    ..Liver-limited disease (LLD) denotes a specific subgroup of metastatic colorectal cancer (mCRC) patients...
  11. ncbi request reprint Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group
    C Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Munich
    Ann Oncol 24:3051-5. 2013
    ..Prognostic factors associated with 60-day mortality would be helpful to identify high-risk patients in advance...
  12. doi request reprint FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
    S Stintzing
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    Ann Oncol 23:1693-9. 2012
    ..In October 2008, an amendment terminated the inclusion of patients with KRAS-mutated tumours. This subgroup of patients is evaluated in the present analysis, while the study is ongoing for patients with KRAS wild-type tumours...
  13. doi request reprint KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
    D P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 139:953-61. 2013
    ..To investigate the impact of different KRAS mutations on treatment with the tyrosine kinase inhibitor sunitinib in SW48 colorectal cancer cell line variants...
  14. pmc Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
    S Stintzing
    Medical Department III, University of Munich, Klinikum Muenchen Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Br J Cancer 105:206-11. 2011
    ..Treatment-related skin toxicity (ST) was evaluated separately for capecitabine and cetuximab. The present analysis investigates the correlation of capecitabine-attributed ST (Cape-ST) and parameters of treatment efficacy...
  15. doi request reprint The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial
    D P Modest
    Department of Medicine III, University of Munich, Munich, Germany
    Int J Cancer 131:980-6. 2012
    ....